Items where authors include "Hillmen, P."

Export as [feed] Atom [feed] RSS
Number of items: 8.

Article

Kulasekararaj, A. orcid.org/0000-0003-3180-3570, Cavenagh, J., Dokal, I. et al. (14 more authors) (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. British Journal of Haematology. ISSN 0007-1048

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Robbe, P. orcid.org/0000-0002-0691-1126, Ridout, K.E., Vavoulis, D.V. orcid.org/0000-0002-3984-1507 et al. (142 more authors) (2022) Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nature Genetics, 54. pp. 1675-1689. ISSN 1061-4036

Rawstron, A.C., Kennedy, B., Moreton, P. et al. (5 more authors) (2004) Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood, 103 (6). pp. 2027-2031. ISSN 0006-4971

Proceedings Paper

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.

Pike, A., Richards, S.J., McKinley, C.E. orcid.org/0000-0003-4006-8846 et al. (8 more authors) (2023) Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations. In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, CA, USA. American Society of Hematology , p. 4097.

Pike, A., Fox, N., McKinley, C.E. orcid.org/0000-0003-4006-8846 et al. (22 more authors) (2023) Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations. In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, CA, USA. American Society of Hematology , p. 2712.

This list was generated on Sat Apr 20 20:46:18 2024 BST.